Background: Dihydroartemisinin 40mg and piperaquine phosphate 320mg (DHA-PQP) drug combination and piperaquin phosphate (PQP) material was first successfully produced in Vietnam \r\n', u'Objective: to study influences of the fixed combination antimalaria drug dihydroartemisinin plus piperaquine in reproductive progress of mice\r\n', u"Subjects and methods: This study was carried out at the Department of Malaria treatment and research, National Institute of Malariology, Parasitology and Entomology (NIMPE), between September, 2006 and March, 2007. The influences of the fixed combination antimalarial drug 40 mg dihydroartemisinin (DHA) plus 320 mg piperaquine phosphate (PQP), with PQP produced firstly in Vietnam, in mice's reproductive progresses were investigated in three generations (including the parent and FI, F2 child generations). \r\n", u'Results: In all three generations, study indices among the treated and control groups were not significantly different (the values P > 0.05). These indices included the rate of fecundation, numbers of fetuses of each mother mouse, numbers of offspring of each mother mouse, mean body weights of offspring. Early lethal fetuses, lately lethal fetuses, monsters and innate abnormally offspring were not found in P, FI and F2 generations. The necessary feeding - day numbers that offspring of P and F 1 generations reached their body weights about 20g were different insignificantly (the values P> 0.05) among the treated and control groups. \r\n', u'Conclusion: The combination DHA-PQP was found to cause no genome mutations in mice at the oral dose of 120 mg per kg per day for 5 consecutive days. \r\n', u'
Dihydroartemisinin ; piperaquine ; fixed combination antimalarial drug ; rate of fecundation ; early lethal fetuses ; lately lethal fetuses ; monsters and innate abnormally offspring ; genome mutations ; fetuses

Background: Piperaquin (PQ) is an anti-malaria drug, which belong to bisquinoline class. Vietnam has successfully produced PQ (both base and phosphate) since 2004. Objective: To evaluate acute oral toxicities of Piperaquine phosphate and the fixed combination anti-malarial drug Dihydroartemisinin plus Piperaquine in mice. Subject and Method: This study was conducted at National Institute of Malariology, Parasitology and Entomology between June and October, 2005. The acute oral toxicities of piperaquine phosphate (PQP) and the fixed combination anti-malaria drug (40 mg dihydroiutemisinin plus 320 mg piperaquine phosphate (DHA-PQP), with the materials produced by Institute of chemistry) in mice were investigated. Result: PQP had a medium toxicity. Inhibition of mice's central nervous systems was the main toxicity exhibition. At the high doses of PQP, mice's convulsion was observed before their deaths. The infralethal dose (LDo), absolute lethal dose (LD100) and mean lethal dose (LD50) of PQP were 900, 2300 and 1643.98 (1537.6 \u2013 1758.92) mg/kg, respectively. The fixed combination DHA-PQP had a less toxicity than PQP powder, with LDo, LD100 and LD50 were 1400, 2800 and 2050.06 (1943.63 \u2013 2157.14) mg per kg of body weight, respectively. Conclusion: At the high doses of DHA-PQP, this combination also inhibited mice's central nervous systems. Mice convulsed strongly before their deaths. All died mice were operated for observing visually their organs such as hearts, livers, kidneys, lungs, vesicles and intestines. No abnormal signals were found.
Piperaquine phosphate ; toxicity ; Dihydroartemisinin

Background: The combination of dihydroartemisinin and piperaquine is interested because of its efficiency and safety in treating malaria. Objective: To evaluate the influences of the fixed combination anti-malarial drug dihydroartemisinin plus piperaquine in constitutions and some biochemical and haematological indices of rabbits. Subject and Method: The sub-chronic toxicity of the fixed combination anti-malarial drug of 40 mg dihydroartemisinin plus 320 mg piperaquine phosphate (DHA-PQP), with the materials produced by Institute of Chemistry, in rabbits was investigated. Rabbits were treated daily by oral route with DHA-PQP at the dose regimens of 64 and 100 mg/kg per day for 28 consecutive days. Result and Conclusion: DHA-PQP did not affect on rabbits' constitutions. Generally, all rabbits had normal ingestions, activities, and defecations. Rabbits' body weights increased regularly along the study period and significantly increased between day 28 and day 0 (P < 0.05). At the dose regimen of 64 mg/kg per day for 28 consecutive days, DHA-PQP did not change significantly rabbits' biochemical indices (including GOT, GPT, bilirubin, creatinine and protein) and haematological. These changes were insignificantly different between the treated and control groups at the same study points (P > 0.05). With the dose regimen of 100 mg/kg, the combination did not affect significantly (P>0.05) on some rabbits' biochemical and haematological indices. But hemoglobin, erythrocyte count and rate of monocytes increased significantly on day 14 comparing to that the control group (P < 0.05) and became in normal limits on day 29 (P > 0.05). Protein concentration also increased significantly on days 14 and 29 comparing to that of day 0 (P < 0.05).
Dihydroartemisinin plus piperaquine combination ; constitutions ; haematological

Background: Hepatitis B is an infectious illness caused by hepatitis B virus (HBV) which infects the liver of hominoidea, including humans, and causes an inflammation called hepatitis. Objectives: The aim of study is to clarify clinical features and molecular characteristics of HBV in chronic HBV-infected patients with A 1899 mutation. Subjects and method: HBV genotype, HBV-ONA level, HBeAg and anti-HBe in 29 chronic HBV-infected patients were determined by PCR-RFLP, Real-time PCR and ELISA, respectively. Mutations were analyzed by direct sequencing. Results: Mutations in core-promoter/precore regions of HBV genome can suppress HBeAg secretion and stimulate HBV-ONA replication. The prevalence of hepatocel- lular carcinoma (HCc): 10/29, liver cirrhosis (LC) : 15/29 are significantly higher than that in chronic hepatitis (CH) : 4/29 (P < 0.001). HbeAg seroconversion rate in CH (75%) is higher than that in HCC \r\n', u'(40%) and in LC (53.3%), but not significant (P > 0.05). ALT level is the highest in CH and the lowest in HCC \r\n', u'(P = 0.02), 8/10 (80%) HCC patients have normal range of ALT. HBV-ONA level in HCC and in LC is significantly higher than that in CH (P = 0.024). The emerging of A 1899 is often accompanied by C/G1753 mutation (37.9%) and dual core-promoter mutation T1762A1764 (79.3%). Conclusion: A1899 mutation can play a role in the pathogenesis of liver diseases in chronic HBV-infected Vietnamese.\r\n', u'
Hepatitis B virus/ growth & ; development ; physiology ; Hepatitis B ; Chronic/ pathology ; transmission

Background: Hepatocellular carcinoma (HCC) is the most common primary hepatic tumor and one of the most common cancers worldwide. HCC is a primary malignancy of hepatocellular origin. Objectives:The aim of study is to combinate therapy of transarterial chemoembolization and percutaneousethanol injection afterward emerging metatasis caused by fine needle aspiration cytology. Subjects and method: A 50 years old male patient with hepatocellular carcinoma having a diameter of tumor more than 5 cm was treated by combination of transarterial chemoembolization and percutaneous ethanol injection from December 2000. Results & Conclusion: Results of study showed that: Transarterial chemoembolization and percutaneous ethanol injection are the two of non-surgical methods for treatment of hepatocellular carcinoma which are most commonly available in applied clinical activities at present. Up to now, the patient's life expectancy after therapy is more than 6 years that means the result of treatment is very good. However, the emerging metatasis into the anterior-right-Iower chest wall that was caused by fine needle aspiration cytology should be reviewed for further evaluating clinical experience, especially in cases with quite clear imaging features of untrasonography and significantly elevated AFP level higher than 200 ng/rnl.
Carcinoma ; Hepatocellular/ pathology ; therapy

Approximately 0.7% of patients taking angiotensin-converting enzyme inhibitors (ACEIs) develop ACEI-induced angioedema (ACEI-IA). With no approved treatments for ACEI-IA, the risk of complications is concerning. Tranexamic acid (TXA) has the potential to prevent intubations and resolve ACEI-IA by inhibiting the downstream production of bradykinin. In this review, we aim to evaluate the safety and efficacy of TXA use in ACEI-IA. We queried the PubMed database for studies involving TXA for ACEI-IA from January 2003 to January 2023. Seven studies met the study inclusion criteria. Our results demonstrate that TXA may improve angioedema symptoms and prevent intubation. In addition, its availability, low cost, and safety profile support its use for improving the symptoms and complications of ACEI-IA in an emergency setting.

Approximately 0.7% of patients taking angiotensin-converting enzyme inhibitors (ACEIs) develop ACEI-induced angioedema (ACEI-IA). With no approved treatments for ACEI-IA, the risk of complications is concerning. Tranexamic acid (TXA) has the potential to prevent intubations and resolve ACEI-IA by inhibiting the downstream production of bradykinin. In this review, we aim to evaluate the safety and efficacy of TXA use in ACEI-IA. We queried the PubMed database for studies involving TXA for ACEI-IA from January 2003 to January 2023. Seven studies met the study inclusion criteria. Our results demonstrate that TXA may improve angioedema symptoms and prevent intubation. In addition, its availability, low cost, and safety profile support its use for improving the symptoms and complications of ACEI-IA in an emergency setting.

Approximately 0.7% of patients taking angiotensin-converting enzyme inhibitors (ACEIs) develop ACEI-induced angioedema (ACEI-IA). With no approved treatments for ACEI-IA, the risk of complications is concerning. Tranexamic acid (TXA) has the potential to prevent intubations and resolve ACEI-IA by inhibiting the downstream production of bradykinin. In this review, we aim to evaluate the safety and efficacy of TXA use in ACEI-IA. We queried the PubMed database for studies involving TXA for ACEI-IA from January 2003 to January 2023. Seven studies met the study inclusion criteria. Our results demonstrate that TXA may improve angioedema symptoms and prevent intubation. In addition, its availability, low cost, and safety profile support its use for improving the symptoms and complications of ACEI-IA in an emergency setting.

Approximately 0.7% of patients taking angiotensin-converting enzyme inhibitors (ACEIs) develop ACEI-induced angioedema (ACEI-IA). With no approved treatments for ACEI-IA, the risk of complications is concerning. Tranexamic acid (TXA) has the potential to prevent intubations and resolve ACEI-IA by inhibiting the downstream production of bradykinin. In this review, we aim to evaluate the safety and efficacy of TXA use in ACEI-IA. We queried the PubMed database for studies involving TXA for ACEI-IA from January 2003 to January 2023. Seven studies met the study inclusion criteria. Our results demonstrate that TXA may improve angioedema symptoms and prevent intubation. In addition, its availability, low cost, and safety profile support its use for improving the symptoms and complications of ACEI-IA in an emergency setting.

Objective: The purpose of this survey was to estimate the prevalence of viral load (VL) suppression and emergence of HIV drug resistance (HIVDR) among individuals receiving antiretroviral therapy (ART) for 36 months or longer in Viet Nam using a nationally representative sampling method. Methods: The survey was conducted between May and August 2014 using a two-stage cluster design. Sixteen ART clinics were selected using probability proportional to proxy size sampling, and patients receiving ART for at least 36 months were consecutively enrolled. Epidemiological information and blood specimens were collected for HIV-1 VL and HIVDR testing; HIVDR was defined by the Stanford University HIVDR algorithm. Results: Overall, 365 eligible individuals were recruited with a mean age of 38.2 years; 68.4% were men. The mean time on ART was 75.5 months (95% confidence interval [CI]: 69.0–81.9 months), and 93.7% of the patients were receiving non-nucleoside reverse transcriptase inhibitor-based regimens. Of the 365 individuals, 345 (94.7%, 95% CI: 64.1–99.4%) had VL below 1000 copies/mL and 19 (4.6%, 95% CI: 2.8-–7.5) had HIVDR mutations. Discussion Our nationally representative survey found a high level of VL suppression and a low prevalence of HIVDR among individuals who received ART for at least 36 months in Viet Nam. Continued surveillance for HIVDR is important for evaluating and improving HIV programs.